Literature DB >> 29534185

Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay.

Francois M J Lamoury1, Sahar Bajis1, Behzad Hajarizadeh1, Alison D Marshall1, Marianne Martinello1, Elena Ivanova2, Beth Catlett3, Yasmin Mowat1, Philippa Marks1, Janaki Amin1,4, Julie Smith5, Nadine Ezard6,7, Victoria Cock8, Jeremy Hayllar9, David H Persing10, Marika Kleman11, Philip Cunningham3, Gregory J Dore1, Tanya L Applegate1, Jason Grebely1.   

Abstract

Point-of-care hepatitis C virus (HCV) RNA testing is advantageous, enabling diagnosis of active infection in a single visit. This study evaluated the sensitivity and specificity of the Xpert HCV Viral Load Finger-Stick assay (Xpert HCV VL FS) for HCV RNA detection (finger-stick) and the Xpert HCV Viral Load assay (plasma) compared with the Abbott RealTime HCV Viral Load assay by venepuncture. Plasma and finger-stick capillary whole-blood samples were collected from participants in an observational cohort in Australia. Of 223 participants enrolled, HCV RNA was detected in 40% of participants (85 of 210) with available Xpert HCV Viral Load testing. Participants receiving HCV therapy were excluded from subsequent analyses (n = 16). Sensitivity of the Xpert HCV Viral Load assay for HCV RNA quantification in plasma collected by venepuncture was 100.0% (95% confidence interval [CI] 96.9%-100.0%) and specificity was 100.0% (95% CI, 94.4%-100.0%). Sensitivity of the Xpert HCV VL FS assay for HCV RNA quantification in samples collected by finger-stick was 100.0% (95% CI, 93.9%-100.0%) and specificity was 100.0% (95% CI, 96.6%-100.0%). The Xpert HCV VL FS test can accurately detect active infection from a finger-stick sample in 1 hour allowing single-visit HCV diagnosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29534185     DOI: 10.1093/infdis/jiy114

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada.

Authors:  Conar R O'Neil; Emily Buss; Sabrina Plitt; Mariam Osman; Carla S Coffin; Carmen L Charlton; Stephen Shafran
Journal:  Can J Public Health       Date:  2019-06-20

2.  Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.

Authors:  Heather Valerio; Maryam Alavi; David Silk; Carla Treloar; Marianne Martinello; Andrew Milat; Adrian Dunlop; Jo Holden; Charles Henderson; Janaki Amin; Phillip Read; Philippa Marks; Louisa Degenhardt; Jeremy Hayllar; David Reid; Carla Gorton; Thao Lam; Gregory J Dore; Jason Grebely
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

Review 3.  Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be?

Authors:  Nadine Kronfli; Jane A Buxton; Lindsay Jennings; Fiona Kouyoumdjian; Alexander Wong
Journal:  Can Liver J       Date:  2019-12-10

4.  Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.

Authors:  Aung H Bwa; Gayatri Nangia; Si T S Win; Soe T Maung; Khin A W Han; Su S Htar; Lei Y Wine; Wint W Ko; Moe P Oo; Naomi K T Hlaing; Julia Palecki; Bao L Loza; Khin M Win; Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2018-12-19

5.  Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs.

Authors:  Stéphane Chevaliez; Mélanie Wlassow; Johann Volant; Françoise Roudot-Thoraval; Antoine Bachelard; Lila Poiteau; Jean-Baptiste Trabut; Christophe Hézode; Anne Bourdel; Stéphanie Dominguez
Journal:  Open Forum Infect Dis       Date:  2020-05-26       Impact factor: 3.835

6.  Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.

Authors:  Alain H Litwin; Martine Drolet; Chizoba Nwankwo; Martha Torrens; Andrej Kastelic; Stephan Walcher; Lorenzo Somaini; Emily Mulvihill; Jochen Ertl; Jason Grebely
Journal:  J Viral Hepat       Date:  2019-06-11       Impact factor: 3.728

7.  Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.

Authors:  Jason Grebely; Phillip Read; Evan B Cunningham; Martin Weltman; Gail V Matthews; Adrian Dunlop; Mark Montebello; Marianne Martinello; Rosie Gilliver; Philippa Marks; Tanya L Applegate; Gregory J Dore
Journal:  Health Sci Rep       Date:  2020-03-15

8.  In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania.

Authors:  Zameer Mohamed; Jessie Mbwambo; John Rwegasha; Nicodem Mgina; Basra Doulla; Promise Mwakale; Edouard Tuaillon; Stephane Chevaliez; Yusuke Shimakawa; Simon D Taylor-Robinson; Mark R Thursz; Ashley S Brown; Maud Lemoine
Journal:  Liver Int       Date:  2019-12-15       Impact factor: 8.754

9.  Diagnostic Performance and Usability of the Genedrive® HCV ID Kit in Two Decentralized Settings in Cameroon and Georgia.

Authors:  Francois M J Lamoury; Richard Njouom; Marie Amougou-Atsama; Euloge Yiagnigni Mfopou; Nino Berishvili; Manana Sologashvili; Emmanuel Fajardo; Agnes Malobela; Aurélien Macé; Maxwell Chirehwa; Maia Alkhazashvili; Elena Ivanova Reipold
Journal:  Diagnostics (Basel)       Date:  2021-04-22

10.  Point-of-Care Screening for a Current Hepatitis C Virus Infection: Influence on Uptake of a Concomitant Offer of HIV Screening.

Authors:  Anna Maria Geretti; Harrison Austin; Giovanni Villa; Dan Hungerford; Colette Smith; Paula Davies; Jillian Williams; Apostolos Beloukas; Wojciech Sawicki; Mark Hopkins
Journal:  Sci Rep       Date:  2018-10-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.